BG108393A - Кристални форми на[r-(r*,r*)]-2-(флуорофенил)-бета, делта-дихидрокси-5-(1-метилетил)-3-фенил-4-[(фениламино)карбонил]-1н-пирол-1-хептанова киселина калциева сол (2:1) (аторвастатин) - Google Patents

Кристални форми на[r-(r*,r*)]-2-(флуорофенил)-бета, делта-дихидрокси-5-(1-метилетил)-3-фенил-4-[(фениламино)карбонил]-1н-пирол-1-хептанова киселина калциева сол (2:1) (аторвастатин) Download PDF

Info

Publication number
BG108393A
BG108393A BG108393A BG10839303A BG108393A BG 108393 A BG108393 A BG 108393A BG 108393 A BG108393 A BG 108393A BG 10839303 A BG10839303 A BG 10839303A BG 108393 A BG108393 A BG 108393A
Authority
BG
Bulgaria
Prior art keywords
wide
atorvastatin
crystalline form
ray powder
broad
Prior art date
Application number
BG108393A
Other languages
Bulgarian (bg)
English (en)
Inventor
Stephen BYRN
David Coates
Karen Gushurst
Ii Henry Morrison
Aeri Park
Petinka Vlahova
Zheng Li
Joseph Krzyzaniak
Original Assignee
Warner-Lambert Company, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23166039&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG108393(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner-Lambert Company, Llc filed Critical Warner-Lambert Company, Llc
Publication of BG108393A publication Critical patent/BG108393A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BG108393A 2001-06-29 2003-11-28 Кристални форми на[r-(r*,r*)]-2-(флуорофенил)-бета, делта-дихидрокси-5-(1-метилетил)-3-фенил-4-[(фениламино)карбонил]-1н-пирол-1-хептанова киселина калциева сол (2:1) (аторвастатин) BG108393A (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30204901P 2001-06-29 2001-06-29

Publications (1)

Publication Number Publication Date
BG108393A true BG108393A (bg) 2004-12-30

Family

ID=23166039

Family Applications (1)

Application Number Title Priority Date Filing Date
BG108393A BG108393A (bg) 2001-06-29 2003-11-28 Кристални форми на[r-(r*,r*)]-2-(флуорофенил)-бета, делта-дихидрокси-5-(1-метилетил)-3-фенил-4-[(фениламино)карбонил]-1н-пирол-1-хептанова киселина калциева сол (2:1) (аторвастатин)

Country Status (40)

Country Link
US (5) US6605729B1 (de)
EP (2) EP1423364B1 (de)
JP (2) JP3965155B2 (de)
KR (1) KR100609371B1 (de)
CN (2) CN101215253A (de)
AP (1) AP1571A (de)
AR (1) AR036118A1 (de)
AU (1) AU2002258092B2 (de)
BG (1) BG108393A (de)
BR (1) BR0210666A (de)
CA (1) CA2450111C (de)
CR (2) CR7170A (de)
CZ (1) CZ20033478A3 (de)
DO (1) DOP2002000413A (de)
EA (1) EA005317B1 (de)
EC (1) ECSP034928A (de)
EE (1) EE200300597A (de)
ES (1) ES2558565T3 (de)
GE (1) GEP20053546B (de)
HR (1) HRP20031039A2 (de)
HU (1) HUP0400381A2 (de)
IL (1) IL158790A0 (de)
MA (1) MA27044A1 (de)
MX (1) MXPA03010266A (de)
MY (1) MY122907A (de)
NO (1) NO326170B1 (de)
NZ (1) NZ529557A (de)
OA (1) OA12636A (de)
PA (1) PA8549501A1 (de)
PE (1) PE20030124A1 (de)
PL (1) PL367943A1 (de)
RS (1) RS100003A (de)
SK (1) SK16002003A3 (de)
SV (1) SV2003001144A (de)
TN (1) TNSN03147A1 (de)
TW (1) TWI319396B (de)
UA (1) UA74075C2 (de)
UY (1) UY27359A1 (de)
WO (1) WO2003004470A1 (de)
ZA (1) ZA200308731B (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
ATE208375T1 (de) 1995-07-17 2001-11-15 Warner Lambert Co Kristallines (r-(r*,r*))-2-(4-fluorphenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- ((phenylamino)carbonyl)-1h-pyrrol-1- heptancarbonsäure hemi calcium salz (atorvastatin)
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US20040072138A1 (en) * 1997-11-25 2004-04-15 Medical University Of South Carolina Attenuation of ischemia/reperfusion injury
US20080275104A1 (en) * 1997-11-25 2008-11-06 Musc Foundation For Research Development Methods of treating juvenile type 1 diabetes mellitus
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
HUP0303765A2 (hu) * 2000-11-03 2004-03-01 Teva Pharmaceutical Industries Ltd. Atorvastatin-hemi-kalcium VII forma és eljárás az előállítására
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
AU2002224952B2 (en) * 2000-12-27 2007-04-05 Teva Pharmaceutical Industries Ltd. Crystalline forms of atorvastatin
MXPA03010266A (es) * 2001-06-29 2004-03-10 Warner Lambert Co Formas cristalinas de la sal de calcio del acido [r-(r*, r*)]-2 -(4-fluorofenil)-¦, d-dihidroxi-5 -(1-metiletil)-3 -fenil-4- [(fenilamino) carbonil ]-1h- pirrol-1-heptanoico (2:1) (atorvastatin).
US7074818B2 (en) * 2001-07-30 2006-07-11 Dr. Reddy's Laboratories Limited Crystalline forms VI and VII of Atorvastatin calcium
US20060020137A1 (en) * 2001-11-29 2006-01-26 Limor Tessler Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
CA2475864A1 (en) * 2002-02-15 2003-08-28 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix
US7122681B2 (en) * 2002-02-19 2006-10-17 Teva Pharmaceutical Industries, Ltd. Desolvation process for the production of atorvastatin hemi-calcium essentially free of bound organic solvent
CA2491051A1 (en) * 2002-09-03 2004-03-18 Morepen Laboratories Limited Atorvastatin calcium form vi or hydrates thereof
AU2003297594A1 (en) * 2002-11-28 2004-06-23 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
EP1424324A1 (de) * 2002-11-28 2004-06-02 Teva Pharmaceutical Industries Limited Kristalline Form F von Atorvastatin
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
WO2005063275A1 (en) * 2003-12-23 2005-07-14 Musc Foundaton For Research Development Methods and compositions for the prevention and treatment of inflammatory diseases or conditions
ES2381473T3 (es) 2004-03-17 2012-05-28 Ranbaxy Laboratories Limited Procedimiento para la preparación de atorvastatina cálcica en forma amorfa
WO2005090301A1 (en) * 2004-03-17 2005-09-29 Ranbaxy Laboratories Limited Crystalline form of atorvastatin hemi calcium
ES2739493T3 (es) 2004-05-05 2020-01-31 Pfizer Prod Inc Formas de sal de de atorvastatina con benetamina
CA2573771C (en) * 2004-07-20 2011-05-10 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta., .gamma.-dihydroxy-5-(1-menthylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
ES2263407T1 (es) * 2004-09-28 2006-12-16 Teva Pharmaceutical Industries Ltd Procedimiento para la preparacion de formas de atorvastatina calcica sustancialmente libres de impurezas.
CA2585836A1 (en) * 2004-10-28 2006-05-04 Warner-Lambert Company Llc Process for forming amorphous atorvastatin
WO2006048894A1 (en) * 2004-11-05 2006-05-11 Morepen Laboratories Limited Novel crystalline forms of atorvastatin calcium and processes for preparing them.
CA2588216A1 (en) * 2004-11-22 2006-05-26 Dexcel Pharma Technologies Ltd. Stable atorvastatin formulations
JP2008521878A (ja) * 2004-12-02 2008-06-26 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 非晶質アトルバスタチンの医薬組成物及びその製造のための方法
EP1688850A1 (de) 2005-02-07 2006-08-09 Sony Ericsson Mobile Communications AB Generischer Parser für elektronische Vorrichtungen
US8506646B2 (en) * 2005-04-29 2013-08-13 Warsaw Orthopedic, Inc. Multi-purpose medical implant devices
US8092464B2 (en) * 2005-04-30 2012-01-10 Warsaw Orthopedic, Inc. Syringe devices and methods useful for delivering osteogenic material
US8084488B2 (en) 2005-11-21 2011-12-27 Pfizer Inc. Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium
KR20080079646A (ko) * 2005-11-21 2008-09-01 테바 파마슈티컬 인더스트리즈 리미티드 아토르바스타틴 제제
EP1923057A1 (de) * 2005-11-21 2008-05-21 Teva Pharmaceutical Industries Ltd Pharmazeutische Atorvastatin-Formulierung
US8080672B2 (en) 2005-12-13 2011-12-20 Teva Pharmaceutical Industries Ltd. Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
US7834195B2 (en) * 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
KR100878140B1 (ko) 2007-01-29 2009-01-12 한미약품 주식회사 아토바스타틴의 스트론튬염 또는 이의 수화물, 및 이를포함하는 약학 조성물
CA2679317A1 (en) * 2007-03-02 2008-09-12 Dong-A Pharm. Co., Ltd. Novel crystal forms of pyrrolylheptanoic acid derivatives
WO2008112887A1 (en) * 2007-03-13 2008-09-18 Musc Foundation For Research Development Methods of treating juvenile type 1 diabetes mellitus
WO2008123953A1 (en) * 2007-04-02 2008-10-16 Merck & Co., Inc. Anti-hypercholesterolemic compound
DE102007052071A1 (de) 2007-10-30 2009-05-07 Stada Arzneimittel Ag Stabilisiertes Atorvastatin
CN101973922B (zh) * 2009-05-27 2013-01-23 天津和美生物技术有限公司 阿伐他汀半锶盐多晶型物、其制备和作为HMG-CoA酶抑制剂的应用
US9334266B2 (en) 2009-09-04 2016-05-10 The University Of Toledo Catalysts and related processes for producing optically pure beta-lactones from aldehydes and compositions produced thereby
CZ201039A3 (cs) 2010-01-19 2011-07-27 Zentiva, K. S Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
WO2013004591A1 (en) 2011-07-01 2013-01-10 Dsm Sinochem Pharmaceuticals Netherlands B.V. Micronized crystals of atorvastatin hemicalcium
CN104945300B (zh) * 2015-06-17 2017-05-10 北京嘉林药业股份有限公司 一种ⅰ型阿托伐他汀钙的纯化方法
CN104983702A (zh) * 2015-07-23 2015-10-21 青岛蓝盛洋医药生物科技有限责任公司 一种治疗高胆固醇血症的药物阿托伐他汀钙组合物片剂
US10450957B2 (en) 2017-01-23 2019-10-22 United Technologies Corporation Gas turbine engine with heat pipe system
US11365170B2 (en) * 2018-07-13 2022-06-21 Kyowa Hakko Bio Co., Ltd. Non-solvate crystal of eucomic acid and method for producing same

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
WO1994016693A1 (en) 1993-01-19 1994-08-04 Warner-Lambert Company Stable oral ci-981 formulation and process of preparing same
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
HRP960312B1 (en) * 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
ATE208375T1 (de) * 1995-07-17 2001-11-15 Warner Lambert Co Kristallines (r-(r*,r*))-2-(4-fluorphenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- ((phenylamino)carbonyl)-1h-pyrrol-1- heptancarbonsäure hemi calcium salz (atorvastatin)
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US6087511A (en) 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
JP2000515882A (ja) 1996-07-29 2000-11-28 ワーナー―ランバート・コンパニー （ｓ）―３，４―ジヒドロキシ酪酸の保護されたエステルを合成するための改善された方法
IN191236B (de) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
SI1235799T1 (en) 1999-11-17 2005-06-30 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
US7411075B1 (en) * 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
SI20425A (sl) 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
WO2001044181A1 (en) * 1999-12-17 2001-06-21 Warner Lambert Research And Development Ireland Limited A process for producing crystalline atorvastatin calcium
DE60024133T2 (de) * 1999-12-17 2006-08-03 Pfizer Science And Technology Ireland Ltd., Dun Laoghaire Herstellungsverfahren auf industrieller basis von atorvastatin trihydrat hemi-kalziumsalz in kristalliner form
HUP0303765A2 (hu) * 2000-11-03 2004-03-01 Teva Pharmaceutical Industries Ltd. Atorvastatin-hemi-kalcium VII forma és eljárás az előállítására
US6528661B2 (en) 2000-11-16 2003-03-04 Teva Pharmaceutical Industries Ltd. Hydrolysis of [R(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
AU2002224952B2 (en) * 2000-12-27 2007-04-05 Teva Pharmaceutical Industries Ltd. Crystalline forms of atorvastatin
WO2002057228A1 (en) 2001-01-17 2002-07-25 Biocon India Limited Atorvastatin calcium
WO2002057229A1 (en) 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
SI20814A (sl) 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
IN190564B (de) 2001-04-11 2003-08-09 Cadila Heathcare Ltd
GB0111077D0 (en) 2001-05-04 2001-06-27 Biochemie Gmbh Organic compounds
MXPA03010266A (es) * 2001-06-29 2004-03-10 Warner Lambert Co Formas cristalinas de la sal de calcio del acido [r-(r*, r*)]-2 -(4-fluorofenil)-¦, d-dihidroxi-5 -(1-metiletil)-3 -fenil-4- [(fenilamino) carbonil ]-1h- pirrol-1-heptanoico (2:1) (atorvastatin).
US7074818B2 (en) * 2001-07-30 2006-07-11 Dr. Reddy's Laboratories Limited Crystalline forms VI and VII of Atorvastatin calcium
US8080672B2 (en) * 2005-12-13 2011-12-20 Teva Pharmaceutical Industries Ltd. Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
US20070265456A1 (en) * 2006-05-09 2007-11-15 Judith Aronhime Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms

Also Published As

Publication number Publication date
ZA200308731B (en) 2004-11-10
MA27044A1 (fr) 2004-12-20
NZ529557A (en) 2005-05-27
RS100003A (en) 2007-02-05
JP2005501032A (ja) 2005-01-13
ES2558565T3 (es) 2016-02-05
EA200301243A1 (ru) 2004-06-24
US20040054193A1 (en) 2004-03-18
KR20040014583A (ko) 2004-02-14
UA74075C2 (en) 2005-10-17
BR0210666A (pt) 2004-10-05
AU2002258092B2 (en) 2007-05-17
EE200300597A (et) 2004-02-16
HUP0400381A2 (hu) 2004-09-28
SV2003001144A (es) 2003-03-18
SK16002003A3 (sk) 2004-12-01
CR9741A (es) 2008-10-31
PE20030124A1 (es) 2003-02-12
EA005317B1 (ru) 2004-12-30
PL367943A1 (en) 2005-03-07
EP3009423A3 (de) 2016-12-28
GEP20053546B (en) 2005-06-10
IL158790A0 (en) 2004-05-12
US20080287521A1 (en) 2008-11-20
US6605729B1 (en) 2003-08-12
AR036118A1 (es) 2004-08-11
UY27359A1 (es) 2003-04-30
WO2003004470A1 (en) 2003-01-16
EP1423364B1 (de) 2015-11-04
AP1571A (en) 2006-02-10
JP2007182460A (ja) 2007-07-19
TNSN03147A1 (en) 2005-12-23
CA2450111A1 (en) 2003-01-16
HRP20031039A2 (en) 2005-10-31
JP3965155B2 (ja) 2007-08-29
PA8549501A1 (es) 2003-09-05
MXPA03010266A (es) 2004-03-10
OA12636A (en) 2006-06-15
EP3009423A2 (de) 2016-04-20
KR100609371B1 (ko) 2006-08-08
TWI319396B (en) 2010-01-11
CN1524073A (zh) 2004-08-25
ECSP034928A (es) 2004-02-26
CR7170A (es) 2004-02-23
CN101215253A (zh) 2008-07-09
AU2002258092C1 (en) 2003-01-21
NO326170B1 (no) 2008-10-13
AP2003002936A0 (en) 2003-12-31
US20060241169A1 (en) 2006-10-26
DOP2002000413A (es) 2003-07-15
US7144915B2 (en) 2006-12-05
CZ20033478A3 (cs) 2004-10-13
EP1423364A1 (de) 2004-06-02
CA2450111C (en) 2006-02-07
MY122907A (en) 2006-05-31
NO20035675D0 (no) 2003-12-18
US20080214651A1 (en) 2008-09-04

Similar Documents

Publication Publication Date Title
BG108393A (bg) Кристални форми на[r-(r*,r*)]-2-(флуорофенил)-бета, делта-дихидрокси-5-(1-метилетил)-3-фенил-4-[(фениламино)карбонил]-1н-пирол-1-хептанова киселина калциева сол (2:1) (аторвастатин)
KR100389518B1 (ko) 결정질[r-(r*,r*)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1h-피롤-1-헵탄산헤미칼슘염(아토르바스타틴)
AU2002258092A1 (en) Crystalline forms of [R-(R*,R*)]-2-(4-Fluorophenyl)-BETA, DELTA-dihydroxy-5-(1-methylethyl)-3-Phenyl-4-[phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
EA000505B1 (ru) Форма iii кристаллической кислой кальциевой соли [r-(r*,r*)]-2-(4-фторфенил)-бета-дельта-дигидрокси-5-(1-метилэтил)-3-фенил-4-[(фениламино)-карбонил]-1н-пиррол-1-гептановой кислоты (аторвастатин)
US8648109B2 (en) Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium
CA2754932C (en) Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
CA2521980C (en) Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)